• 26087 Citations
  • 66 h-Index
19982020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

  • 26087 Citations
  • 66 h-Index
  • 291 Article
  • 8 Review article
  • 2 Comment/debate
  • 2 Letter
Filter
Article
2020

A newly developed capture-based sequencing panel for genomic assay of lung cancer

Im, S. W., Chae, J., Jang, S. S., Choi, J., Yun, J., Cha, S., Kwon, N. J., Jeon, Y. K., Hwang, Y., Kim, M., Kim, T. M., Kim, D. W., Kim, J. I. & Kim, Y. T., 1 Jul 2020, In : Genes and Genomics. 42, 7, p. 751-759 9 p.

Research output: Contribution to journalArticle

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study

Tan, D. S. W., Leighl, N. B., Riely, G. J., Yang, J. C. H., Sequist, L. V., Wolf, J., Seto, T., Felip, E., Aix, S. P., Jonnaert, M., Pan, C., Tan, E. Y., Ko, J., Moody, S. E. & Kim, D. W., Jun 2020, In : The Lancet Respiratory Medicine. 8, 6, p. 561-572 12 p.

Research output: Contribution to journalArticle

4 Scopus citations

Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis

Cho, B. C., Kim, D. W., Park, K., Lee, J. S., Yoo, S. S., Kang, J. H., Lee, S. Y., Kim, C. H., Jang, S. H., Kim, Y. C., Yoon, H. K., Han, J. Y. & Kim, S. W., 3 Mar 2020, In : Current Medical Research and Opinion. 36, 3, p. 477-482 6 p.

Research output: Contribution to journalArticle

Clinical application of next-generation sequencing–based panel to BRAF wild-type advanced melanoma identifies key oncogenic alterations and therapeutic strategies

Park, C., Kim, M., Kim, M. J., Kim, H., Ock, C. Y., Keam, B., Kim, T. M., Kim, D. W., Kim, J. I. & Heo, D. S., 1 Mar 2020, In : Molecular cancer therapeutics. 19, 3, p. 937-944 8 p.

Research output: Contribution to journalArticle

1 Scopus citations

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Huber, R. M., Hansen, K. H., Paz-Ares Rodríguez, L., West, H. L., Reckamp, K. L., Leighl, N. B., Tiseo, M., Smit, E. F., Kim, D. W., Gettinger, S. N., Hochmair, M. J., Kim, S. W., Langer, C. J., Ahn, M. J., Kim, E. S., Kerstein, D., Groen, H. J. M. & Camidge, D. R., Mar 2020, In : Journal of Thoracic Oncology. 15, 3, p. 404-415 12 p.

Research output: Contribution to journalArticle

Open Access
2 Scopus citations
1 Scopus citations

Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in non‑small cell lung cancer

Park, S., Lim, J. M., Chun, J. N., Lee, S., Kim, T. M., Kim, D. W., Kim, S. Y., Bae, D. J., Bae, S. M., So, I., Kim, H. G., Choi, J. Y. & Jeon, J. H., Feb 2020, In : International Journal of Oncology. 56, 2, p. 559-567 9 p.

Research output: Contribution to journalArticle

Open Access

Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial

Lee, G. W., Go, S. I., Kim, D. W., Kim, H. G., Kim, J. H., An, H. J., Jang, J. S., Kim, B. S., Hahn, S. & Heo, D. S., 1 Jan 2020, In : Thoracic Cancer. 11, 1, p. 62-71 10 p.

Research output: Contribution to journalArticle

Open Access

Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies

Ahn, M. J., Han, J. Y., Kim, D. W., Cho, B. C., Kang, J. H., Kim, S. W., Yang, J. C. H., Mitsudomi, T. & Lee, J. S., 1 Jan 2020, In : Cancer Research and Treatment. 52, 1, p. 284-291 8 p.

Research output: Contribution to journalArticle

Open Access

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

Ou, S. H. I., Gadgeel, S. M., Barlesi, F., Yang, J. C. H., De Petris, L., Kim, D. W., Govindan, R., Dingemans, A. M., Crino, L., Léna, H., Popat, S., Ahn, J. S., Dansin, E., Mitry, E., Müller, B., Bordogna, W., Balas, B., Morcos, P. N. & Shaw, A. T., Jan 2020, In : Lung Cancer. 139, p. 22-27 6 p.

Research output: Contribution to journalArticle

2 Scopus citations
2019

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Ahn, M. J., Han, J. Y., Lee, K. H., Kim, S. W., Kim, D. W., Lee, Y. G., Cho, E. K., Kim, J. H., Lee, G. W., Lee, J. S., Min, Y. J., Kim, J. S., Lee, S. S., Kim, H. R., Hong, M. H., Ahn, J. S., Sun, J. M., Kim, H. T., Lee, D. H., Kim, S. & 1 others, Cho, B. C., Dec 2019, In : The Lancet Oncology. 20, 12, p. 1681-1690 10 p.

Research output: Contribution to journalArticle

5 Scopus citations
Open Access

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer

Heo, J. Y., Park, C., Keam, B., Ock, C. Y., Kim, M., Kim, T. M., Kim, D. W., Kim, S. H., Kim, Y. J., Lee, J. S. & Heo, D. S., 1 Nov 2019, In : Thoracic Cancer. 10, 11, p. 2117-2123 7 p.

Research output: Contribution to journalArticle

Open Access

Poor prognostic factors in human papillomavirus-positive head and neck cancer: Who might not be candidates for de-escalation treatment?

Yoo, S. H., Ock, C. Y., Keam, B., Park, S. J., Kim, T. M., Kim, J. H., Jeon, Y. K., Chung, E. J., Kwon, S. K., Hah, J. H., Kwon, T. K., Jung, K. C., Kim, D. W., Wu, H. G., Sung, M. W. & Heo, D. S., Nov 2019, In : Korean Journal of Internal Medicine. 34, 6, p. 1313-1323 11 p.

Research output: Contribution to journalArticle

Open Access
5 Scopus citations
4 Scopus citations

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Antonia, S. J., Balmanoukian, A., Brahmer, J., Ou, S. H. I., Hellmann, M. D., Kim, S. W., Ahn, M. J., Kim, D. W., Gutierrez, M., Liu, S. V., Schöffski, P., Jäger, D., Jamal, R., Jerusalem, G., Lutzky, J., Nemunaitis, J., Calabrò, L., Weiss, J., Gadgeel, S., Bhosle, J. & 11 others, Ascierto, P. A., Rebelatto, M. C., Narwal, R., Liang, M., Xiao, F., Antal, J., Abdullah, S., Angra, N., Gupta, A. K., Khleif, S. N. & Segal, N. H., Oct 2019, In : Journal of Thoracic Oncology. 14, 10, p. 1794-1806 13 p.

Research output: Contribution to journalArticle

Open Access
16 Scopus citations

Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Lee, Y., Kim, T. M., Kim, D. W., Kim, S., Kim, M., Keam, B., Ku, J. L. & Heo, D. S., 1 Sep 2019, In : Journal of Thoracic Oncology. 14, 9, p. 1556-1566 11 p.

Research output: Contribution to journalArticle

3 Scopus citations
Open Access
1 Scopus citations
4 Scopus citations

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial

Kim, D. W., Lee, D. H., Han, J. Y., Lee, J., Cho, B. C., Kang, J. H., Lee, K. H., Cho, E. K., Kim, J. S., Min, Y. J., Cho, J. Y., An, H. J., Kim, H. G., Lee, K. H., Kim, B. S., Jang, I. J., Yoon, S., Han, O. P., Noh, Y. S., Hong, K. Y. & 1 others, Park, K., Sep 2019, In : Lung Cancer. 135, p. 66-72 7 p.

Research output: Contribution to journalArticle

1 Scopus citations

Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib

Kim, S., Kim, T. M., Kim, D. W., Kim, S., Kim, M., Ahn, Y. O., Keam, B. & Heo, D. S., 1 Jul 2019, In : Cancer Research and Treatment. 51, 3, p. 951-962 12 p.

Research output: Contribution to journalArticle

Open Access
11 Scopus citations
Open Access
7 Scopus citations

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Shaw, A. T., Riely, G. J., Bang, Y. J., Kim, D. W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., Wang, S. C., Wilner, K. D., Clark, J. W. & Ou, S. H. I., 1 Jul 2019, In : Annals of Oncology. 30, 7, p. 1121-1126 6 p., mdz131.

Research output: Contribution to journalArticle

Open Access
43 Scopus citations

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

Cho, B. C., Obermannova, R., Bearz, A., McKeage, M., Kim, D. W., Batra, U., Borra, G., Orlov, S., Kim, S. W., Geater, S. L., Postmus, P. E., Laurie, S. A., Park, K., Yang, C. T., Ardizzoni, A., Bettini, A. C., de Castro, G., Kiertsman, F., Chen, Z., Lau, Y. Y. & 3 others, Viraswami-Appanna, K., Passos, V. Q. & Dziadziuszko, R., Jul 2019, In : Journal of Thoracic Oncology. 14, 7, p. 1255-1265 11 p.

Research output: Contribution to journalArticle

Open Access
10 Scopus citations

Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer

Choi, M., Keam, B., Ock, C. Y., Kim, M., Kim, T. M., Kim, D. W. & Heo, D. S., Jul 2019, In : Clinical Lung Cancer. 20, 4, p. e442-e451

Research output: Contribution to journalArticle

2 Scopus citations

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

Schuler, M., Tan, E. H., O’Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C. H., Lee, K. H., Lu, S., Shi, Y., Kim, S. W., Laskin, J., Kim, D. W., Arvis, C. D., Kölbeck, K., Massey, D., Märten, A., Paz-Ares, L. & Park, K., 1 Jun 2019, In : Journal of Cancer Research and Clinical Oncology. 145, 6, p. 1569-1579 11 p.

Research output: Contribution to journalArticle

5 Scopus citations

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

Barlesi, F., Garon, E. B., Kim, D. W., Felip, E., Han, J. Y., Kim, J. H., Ahn, M. J., Fidler, M. J., Gubens, M. A., de Castro, G., Surmont, V., Li, Q., Deitz, A. C., Lubiniecki, G. M. & Herbst, R. S., May 2019, In : Journal of Thoracic Oncology. 14, 5, p. 793-801 9 p.

Research output: Contribution to journalArticle

8 Scopus citations

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

Chih-Hsin Yang, J., Shepherd, F. A., Kim, D. W., Lee, G. W., Lee, J. S., Chang, G. C., Lee, S. S., Wei, Y. F., Lee, Y. G., Laus, G., Collins, B., Pisetzky, F. & Horn, L., May 2019, In : Journal of Thoracic Oncology. 14, 5, p. 933-939 7 p.

Research output: Contribution to journalArticle

Open Access
24 Scopus citations

Tumor-associated macrophages enhance tumor hypoxia and aerobic glycolysis

Jeong, H., Kim, S., Hong, B. J., Lee, C. J., Kim, Y. E., Bok, S., Oh, J. M., Gwak, S. H., Yoo, M. Y., Lee, M. S., Chung, S. J., Defrêne, J., Tessier, P., Pelletier, M., Jeon, H., Roh, T. Y., Kim, B., Kim, K. H., Ju, J. H., Kim, S. & 12 others, Lee, Y. J., Kim, D. W., Kim, I. H., Kim, H. J., Park, J. W., Lee, Y. S., Lee, J. S., Cheon, G. J., Weissman, I. L., Chung, D. H., Jeon, Y. K. & Ahn, G. O., 15 Feb 2019, In : Cancer Research. 79, 4, p. 795-806 12 p.

Research output: Contribution to journalArticle

Open Access
27 Scopus citations

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial

Herbst, R. S., Baas, P., Perez-Gracia, J. L., Felip, E., Kim, D. W., Han, J. Y., Molina, J. R., Kim, J. H., Dubos Arvis, C., Ahn, M. J., Majem, M., Fidler, M. J., Surmont, V., De Castro, G., Garrido, M., Shentu, Y., Emancipator, K., Samkari, A., Jensen, E. H., Lubiniecki, G. M. & 1 others, Garon, E. B., 1 Feb 2019, In : Annals of Oncology. 30, 2, p. 281-289 9 p.

Research output: Contribution to journalArticle

21 Scopus citations
10 Scopus citations

Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study

Jung, M., Kim, S., Lee, J. K., Yoon, S. O., Park, H. S., Hong, S. W., Park, W. S., Kim, J. E., Kim, J., Keam, B., Kim, H. J., Kang, H. J., Kim, D. W., Jung, K. C., Kim, Y. T., Heo, D. S., Kim, T. M. & Jeon, Y. K., 1 Jan 2019, In : Oncologist. 24, 8, p. e740-e748

Research output: Contribution to journalArticle

3 Scopus citations

Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer

Kim, D. W., Kim, H. G., Kim, J. H., Park, K., Kim, H. K., Jang, J. S., Kim, B. S., Kang, J. H., Lee, K. H., Kim, S. W., Ryoo, H. M., Kim, J. S., Lee, K. H., Kwon, J. H., Choi, J. H., Shin, S. W., Hahn, S. & Heo, D. S., 1 Jan 2019, In : Cancer Research and Treatment. 51, 1, p. 119-127 9 p.

Research output: Contribution to journalArticle

8 Scopus citations
1 Scopus citations

Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies

Gadgeel, S., Shaw, A. T., Barlesi, F., Crino, L., Yang, J. C. H., Dingemans, A. M., Kim, D. W., Marinis, F. D., Schulz, M., Liu, S., Gupta, R., Smoljanovic, V. & Ou, S. H. I., 1 Jan 2019, In : Lung Cancer: Targets and Therapy. 10, p. 125-130 6 p.

Research output: Contribution to journalArticle

Open Access
6 Scopus citations

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP

Cho, K. M., Keam, B., Ha, H., Kim, M., Jung, J. W., Song, W. J., Kim, T. M., Jeon, Y. K., Kang, H. R., Kim, D. W., Kim, C. W. & Heo, D. S., 2019, In : Korean Journal of Internal Medicine. 34, 4, p. 885-893 9 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations
2018

Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C. H., Han, J. Y., Lee, J. S., Hochmair, M. J., Li, J. Y. C., Chang, G. C., Lee, K. H., Gridelli, C., Delmonte, A., Garcia Campelo, R., Kim, D. W., Bearz, A., Griesinger, F., Morabito, A., Felip, E., Califano, R., Ghosh, S. & 7 others, Spira, A., Gettinger, S. N., Tiseo, M., Gupta, N., Haney, J., Kerstein, D. & Popat, S., 22 Nov 2018, In : New England Journal of Medicine. 379, 21, p. 2027-2039 13 p.

Research output: Contribution to journalArticle

173 Scopus citations

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

Wu, Y. L., Zhang, L., Kim, D. W., Liu, X., Lee, D. H., Yang, J. C. H., Ahn, M. J., Vansteenkiste, J. F., Su, W. C., Felip, E., Chia, V., Glaser, S., Pultar, P., Zhao, S., Peng, B., Akimov, M. & Tan, D. S. W., 1 Nov 2018, In : Journal of Clinical Oncology. 36, 31, p. 3101-3109 9 p.

Research output: Contribution to journalArticle

59 Scopus citations

Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non–small-cell lung cancer and brain metastases in two clinical trials

Ross Camidge, D., Kim, D. W., Tiseo, M., Langer, C. J., Ahn, M. J., Shaw, A. T., Huber, R. M., Hochmair, M. J., Lee, D. H., Bazhenova, L. A., Gold, K. A., Ou, S. H. I., West, H. L., Reichmann, W., Haney, J., Clackson, T., Kerstein, D. & Gettinger, S. N., 10 Sep 2018, In : Journal of Clinical Oncology. 36, 26, p. 2693-2701 9 p.

Research output: Contribution to journalArticle

47 Scopus citations

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer

Cho, B. C., Dy, G. K., Govindan, R., Kim, D. W., Pennell, N. A., Zalcman, G., Besse, B., Kim, J. H., Koca, G., Rajagopalan, P., Langer, S., Ocker, M., Nogai, H. & Barlesi, F., Sep 2018, In : Lung Cancer. 123, p. 14-21 8 p.

Research output: Contribution to journalArticle

8 Scopus citations

Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in alk-mutation-positive non–small-cell lung cancer

Solomon, B. J., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Tang, Y., Wilner, K. D., Blackhall, F. & Mok, T. S., 1 Aug 2018, In : Journal of Clinical Oncology. 36, 22, p. 2251-2258 8 p.

Research output: Contribution to journalArticle

98 Scopus citations

Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy

Lee, J. S., Lee, K. H., Cho, E. K., Kim, D. W., Kim, S. W., Kim, J. H., Cho, B. C., Kang, J. H., Han, J. Y., Min, Y. J. & Park, K., Aug 2018, In : Lung Cancer. 122, p. 234-242 9 p.

Research output: Contribution to journalArticle

6 Scopus citations
2 Scopus citations

Crizotinib versus chemotherapy in asian patients with alk-positive advanced non-small cell lung cancer

Nishio, M., Kim, D. W., Wu, Y. L., Nakagawa, K., Solomon, B. J., Shaw, A. T., Hashigaki, S., Ohki, E., Usari, T., Paolini, J., Polli, A., Wilner, K. D. & Mok, T., 1 Jul 2018, In : Cancer Research and Treatment. 50, 3, p. 691-700 10 p.

Research output: Contribution to journalArticle

16 Scopus citations

The effect of hospice consultation on aggressive treatment of lung cancer

Yoo, S. H., Keam, B., Kim, M. S., Kim, T. M., Kim, D-W. & Heo, D. S., 1 Jul 2018, In : Cancer Research and Treatment. 50, 3, p. 720-728 9 p.

Research output: Contribution to journalArticle

4 Scopus citations
4 Scopus citations

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

ATLANTIC Investigators, Apr 2018, In : The Lancet Oncology. 19, 4, p. 521-536 16 p.

Research output: Contribution to journalArticle

155 Scopus citations

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

Felip, E., Barlesi, F., Besse, B., Chu, Q., Gandhi, L., Kim, S. W., Carcereny, E., Sequist, L. V., Brunsvig, P., Chouaid, C., Smit, E. F., Groen, H. J. M., Kim, D. W., Park, K., Avsar, E., Szpakowski, S., Akimov, M. & Garon, E. B., Apr 2018, In : Journal of Thoracic Oncology. 13, 4, p. 576-584 9 p.

Research output: Contribution to journalArticle

26 Scopus citations

Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer

Ramalingam, S. S., Yang, J. C. H., Lee, C. K., Kurata, T., Kim, D. W., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., Ghiorghiu, S., Stetson, D., Markovets, A., Barrett, J. C., Thress, K. S. & Jänne, P. A., 20 Mar 2018, In : Journal of Clinical Oncology. 36, 9, p. 841-849 9 p.

Research output: Contribution to journalArticle

190 Scopus citations

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALKþ) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Gadgeel, S., Peters, S., Mok, T., Shaw, A. T., Kim, D. W., Ou, S. I., Pérol, M., Wrona, A., Novello, S., Rosell, R., Zeaiter, A., Liu, T., Nüesch, E., Balas, B. & Camidge, D. R., 1 Jan 2018, In : Annals of Oncology. 29, 11, p. 2214-2222 9 p.

Research output: Contribution to journalArticle

59 Scopus citations

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

Gadgeel, S., Shaw, A. T., Barlesi, F., Crinò, L., Yang, J. C. H., Dingemans, A. M. C., Kim, D. W., De Marinis, F., Schulz, M., Liu, S., Gupta, R., Kotb, A. & Ou, S. H. I., 1 Jan 2018, In : British Journal of Cancer. 118, 1, p. 38-42 5 p.

Research output: Contribution to journalArticle

11 Scopus citations

Phase II study of crizotinib in east asian patients with ROS1-positive advanced non–small-cell lung cancer

Wu, Y. L., Yang, J. C. H., Kim, D. W., Lu, S., Zhou, J., Seto, T., Yang, J. J., Yamamoto, N., Ahn, M. J., Takahashi, T., Yamanaka, T., Kemner, A., Roychowdhury, D., Paolini, J., Usari, T., Wilner, K. D. & Goto, K., 1 Jan 2018, In : Journal of Clinical Oncology. 36, 14, p. 1405-1411 7 p.

Research output: Contribution to journalArticle

75 Scopus citations
2017

Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study

Ott, P. A., Elez, E., Hiret, S., Kim, D. W., Morosky, A., Saraf, S., Piperdi, B. & Mehnert, J. M., 1 Dec 2017, In : Journal of Clinical Oncology. 35, 34, p. 3823-3829 7 p.

Research output: Contribution to journalArticle

175 Scopus citations

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

Ahn, M. J., Kim, D. W., Cho, B. C., Kim, S. W., Lee, J. S., Ahn, J. S., Kim, T. M., Lin, C. C., Kim, H. R., John, T., Kao, S., Goldman, J. W., Su, W. C., Natale, R., Rabbie, S., Harrop, B., Overend, P., Yang, Z. & Yang, J. C. H., Nov 2017, In : The Lancet Respiratory Medicine. 5, 11, p. 891-902 12 p.

Research output: Contribution to journalArticle

37 Scopus citations

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

Yang, J. C. H., Ou, S. H. I., De Petris, L., Gadgeel, S., Gandhi, L., Kim, D. W., Barlesi, F., Govindan, R., Dingemans, A. M. C., Crino, L., Lena, H., Popat, S., Ahn, J. S., Dansin, E., Golding, S., Bordogna, W., Balas, B., Morcos, P. N., Zeaiter, A. & Shaw, A. T., Oct 2017, In : Journal of Thoracic Oncology. 12, 10, p. 1552-1560 9 p.

Research output: Contribution to journalArticle

35 Scopus citations

ClonalHistory & genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas

Lee, J. K., Lee, J., Kim, S., Kim, S., Youk, J., Park, S., An, Y., Keam, B., Kim, D. W., Heo, D. S., Kim, Y. T., Kim, J. S., Kim, S. H., Lee, J. S., Lee, S. H., Park, K., Ku, J. L., Jeon, Y. K., Chung, D. H., Park, P. J. & 3 others, Kim, J., Kim, T. M. & Ju, Y. S., 10 Sep 2017, In : Journal of Clinical Oncology. 35, 26, p. 3065-3074 10 p.

Research output: Contribution to journalArticle

119 Scopus citations

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Cho, B. C., Kim, D. W., Bearz, A., Laurie, S. A., McKeage, M., Borra, G., Park, K., Kim, S. W., Ghosn, M., Ardizzoni, A., Maiello, E., Greystoke, A., Yu, R., Osborne, K., Gu, W., Scott, J. W., Passos, V. Q., Lau, Y. Y. & Wrona, A., Sep 2017, In : Journal of Thoracic Oncology. 12, 9, p. 1357-1367 11 p.

Research output: Contribution to journalArticle

73 Scopus citations

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria

Gandhi, L., Ignatius Ou, S. H., Shaw, A. T., Barlesi, F., Dingemans, A. M. C., Kim, D. W., Camidge, D. R., Hughes, B. G. M., Yang, J. C. H., de Castro, J., Crino, L., Léna, H., Do, P., Golding, S., Bordogna, W., Zeaiter, A., Kotb, A. & Gadgeel, S., Sep 2017, In : European Journal of Cancer. 82, p. 27-33 7 p.

Research output: Contribution to journalArticle

18 Scopus citations

Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer

ALEX Trial Investigators, 31 Aug 2017, In : New England Journal of Medicine. 377, 9, p. 829-838 10 p.

Research output: Contribution to journalArticle

675 Scopus citations

Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: A randomized, multicenter phase II trial

Kim, D. W., Tiseo, M., Ahn, M. J., Reckamp, K. L., Hansen, K. H., Kim, S. W., Huber, R. M., West, H. L., Groen, H. J. M., Hochmair, M. J., Leighl, N. B., Gettinger, S. N., Langer, C. J., Rodríguez, L. G. P. A., Smit, E. F., Kim, E. S., Reichmann, W., Haluska, F. G., Kerstein, D. & Camidge, D. R., 1 Aug 2017, In : Journal of Clinical Oncology. 35, 22, p. 2490-2498 9 p.

Research output: Contribution to journalArticle

261 Scopus citations

Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

Blackhall, F., Ross Camidge, D., Shaw, A. T., Soria, J. C., Solomon, B. J., Mok, T., Hirsh, V., Jänne, P. A., Shi, Y., Yang, P. C., De Pas, T., Hida, T., De Castro Carpeño, J., Lanzalone, S., Polli, A., Iyer, S., Reisman, A., Wilner, K. D. & Kim, D. W., Aug 2017, In : ESMO Open. 2, 3, e000219.

Research output: Contribution to journalArticle

33 Scopus citations

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer

Park, S., Kim, J. Y., Lee, S. H., Suh, B., Keam, B., Kim, T. M., Kim, D. W. & Heo, D. S., May 2017, In : Korean Journal of Internal Medicine. 32, 3, p. 514-522 9 p.

Research output: Contribution to journalArticle

9 Scopus citations

Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type

Sim, S. H., Kim, S., Kim, T. M., Jeon, Y. K., Nam, S. J., Ahn, Y. O., Keam, B., Park, H. H., Kim, D. W., Kim, C. W. & Heo, D. S., May 2017, In : American Journal of Pathology. 187, 5, p. 980-986 7 p.

Research output: Contribution to journalArticle

23 Scopus citations

Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component

Yang, J. C. H., Ahn, M. J., Kim, D. W., Ramalingam, S. S., Sequist, L. V., Su, W. C., Kim, S. W., Kim, J. H., Planchard, D., Felip, E., Blackhall, F., Haggstrom, D., Yoh, K., Novello, S., Gold, K., Hirashima, T., Lin, C. C., Mann, H., Cantarini, M., Ghiorghiu, S. & 1 others, Jänne, P. A., 20 Apr 2017, In : Journal of Clinical Oncology. 35, 12, p. 1288-1296 9 p.

Research output: Contribution to journalArticle

236 Scopus citations

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042)

Kim, D. W., Garon, E. B., Jatoi, A., Keefe, D. M., Lacouture, M. E., Sonis, S., Gernhardt, D., Wang, T., Giri, N., Doherty, J. P., Nadanaciva, S., O'Connell, J., Sbar, E. & Cho, B. C., 1 Apr 2017, In : Lung Cancer. 106, p. 76-82 7 p.

Research output: Contribution to journalArticle

3 Scopus citations

Phase II study of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancer

Kim, M., Keam, B., Kim, T. M., Kim, H. G., Kim, J. S., Lee, S. S., Shin, S. H., Kim, M. K., Park, K. U., Kim, D. W., Yun, H. J., Lee, J. S. & Heo, D. S., 1 Apr 2017, In : Cancer Research and Treatment. 49, 2, p. 416-422 7 p.

Research output: Contribution to journalArticle

12 Scopus citations

Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles

Keam, B., Kim, M. K., Choi, Y., Choi, S. J., Choe, P. G., Lee, K. H., Kim, T. M., Kim, T. Y., Oh, D. Y., Kim, D. W., Im, S. A., Kim, N. J., Heo, D. S., Park, W. B. & Oh, M. D., 1 Mar 2017, In : Cancer. 123, 5, p. 841-848 8 p.

Research output: Contribution to journalArticle

11 Scopus citations
11 Scopus citations

Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel

Kang, R. Y., Yoo, K. S., Han, H. J., Lee, J. Y., Lee, S. H., Kim, D. W. & Lee, Y. J., 1 Feb 2017, In : Supportive Care in Cancer. 25, 2, p. 429-437 9 p.

Research output: Contribution to journalArticle

2 Scopus citations
23 Scopus citations

Clinical outcomes of stereotactic ablative radiotherapy in patients with pulmonary metastasis

Jang, B. S., Kim, H. J., Kim, B. H., Kim, D. W., Kim, Y. T., Kim, Y. W., Jang, M. J. & Wu, H. G., 1 Jan 2017, In : Japanese Journal of Clinical Oncology. 47, 1, p. 61-66 6 p.

Research output: Contribution to journalArticle

1 Scopus citations

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial

Paz-Ares, L., Tan, E. H., O'Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J. C. H., Mok, T., Lee, K. H., Lu, S., Shi, Y., Lee, D. H., Laskin, J., Kim, D. W., Laurie, S. A., Kölbeck, K., Fan, J., Dodd, N., Märten, A. & Park, K., 2017, In : Annals of Oncology. 28, 2, p. 270-277 8 p.

Research output: Contribution to journalArticle

188 Scopus citations

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

Kim, H. R., Jang, J. S., Sun, J. M., Ahn, M. J., Kim, D. W., Jung, I., Lee, K. H., Kim, J. H., Lee, D. H., Kim, S. W. & Cho, B. C., 2017, In : Oncotarget. 8, 9, p. 15943-15951 9 p.

Research output: Contribution to journalArticle

4 Scopus citations

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: A phase II clinical trial

Lee, S. H., Lee, J. K., Ahn, M. J., Kim, D. W., Sun, J. M., Keam, B., Kim, T. M., Heo, D. S., Ahn, J. S., Choi, Y. L., Min, H. S., Jeon, Y. K. & Park, K., 2017, In : Annals of Oncology. 28, 2, p. 292-297 6 p.

Research output: Contribution to journalArticle

67 Scopus citations
2016

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

Yang, Z., Guo, Q., Wang, Y., Chen, K., Zhang, L., Cheng, Z., Xu, Y., Yin, X., Bai, Y., Rabbie, S., Kim, D. W., Ahn, M. J., Yang, J. C. H. & Zhang, X., 7 Dec 2016, In : Science Translational Medicine. 8, 368, 368ra172.

Research output: Contribution to journalArticle

45 Scopus citations

Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer

Gadgeel, S. M., Shaw, A. T., Govindan, R., Gandhi, L., Socinski, M. A., Camidge, D. R., De Petris, L., Kim, D. W., Chiappori, A., Moro-Sibilot, D. L., Duruisseaux, M., Crino, L., De Pas, T., Dansin, E., Tessmer, A., Yang, J. C. H., Han, J. Y., Bordogna, W., Golding, S., Zeaiter, A. & 1 others, Ou, S. H. I., 1 Dec 2016, In : Journal of Clinical Oncology. 34, 34, p. 4079-4085 7 p.

Research output: Contribution to journalArticle

86 Scopus citations

Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity

Ballard, P., Yates, J. W. T., Yang, Z., Kim, D. W., Yang, J. C. H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., Box, M., Johnström, P., Varnäs, K., Malmquist, J., Thress, K. S., Jänne, P. A. & Cross, D., 15 Oct 2016, In : Clinical Cancer Research. 22, 20, p. 5130-5140 11 p.

Research output: Contribution to journalArticle

265 Scopus citations
16 Scopus citations

Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: Results from PROFILE 1014

Solomon, B. J., Cappuzzo, F., Felip, E., Blackhall, F. H., Costa, D. B., Kim, D. W., Nakagawa, K., Wu, Y. L., Mekhail, T., Paolini, J., Tursi, J., Usari, T., Wilner, K. D., Selaru, P. & Mok, T. S. K., 20 Aug 2016, In : Journal of Clinical Oncology. 34, 24, p. 2858-2865 8 p.

Research output: Contribution to journalArticle

125 Scopus citations
67 Scopus citations

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial

Park, K., Tan, E. H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C. H., Lee, K. H., Lu, S., Shi, Y., Kim, S. W., Laskin, J., Kim, D. W., Arvis, C. D., Kölbeck, K., Laurie, S. A., Tsai, C. M., Shahidi, M., Kim, M. & 3 others, Massey, D., Zazulina, V. & Paz-Ares, L., 1 May 2016, In : The Lancet Oncology. 17, 5, p. 577-589 13 p.

Research output: Contribution to journalArticle

443 Scopus citations

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

Ock, C. Y., Keam, B., Kim, S., Lee, J. S., Kim, M. S., Kim, T. M., Jeon, Y. K., Kim, D-W., Chung, D. & Heo, D. S., 1 May 2016, In : Clinical Cancer Research. 22, 9, p. 2261-2270 10 p.

Research output: Contribution to journalArticle

102 Scopus citations

Graves’ patient with thymic expression of thyrotropin receptors and dynamic changes in thymic hyperplasia proportional to graves’ disease activity

Song, Y. S., Won, J. K., Kim, M. J., Lee, J. H., Kim, D. W., Chung, J. K., Park, D. J. & Park, Y. J., May 2016, In : Yonsei Medical Journal. 57, 3, p. 795-798 4 p.

Research output: Contribution to journalArticle

3 Scopus citations